Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
DaVita Inc.
DVA
NYSE·Healthcare·Medical - Care Facilities·Mkt cap $14.6B
$234.91
▲ +3.02%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$101.00 - $236.51
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 60.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive nationwide dialysis center network
- Comprehensive kidney care ecosystem
- Advanced clinical research capabilities
- Integrated care management expertise
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Rising chronic kidney disease prevalence
Value
Attractively priced below Healthcare Facilities peer average
Momentum
Hot
+56.6% over 3m
Quality
Stable
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying DVA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 5, 2026
Reported EPS of $2.87 vs $2.33 consensus (+23.2% surprise). Revenue of $3.4B vs $3.4B expected (+1.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+23.2%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+5%
+5%
+6%
+5%
+10%
+6%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$3.2B
$3.3B
$3.3B
$3.2B
$3.4B
$3.4B
$3.6B
$3.4B
Margins · last 8Q
Gross
—
Operating
—
Profit
5.8%
Wall Street consensus
5 analysts · 40% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
40%
Hold
60%
Sell
0%
Median Price Target
$199.50
▼ -15.1% vs $234.91
Latest: TD Cowen · May 11, 2026
3 analysts covering